Blog
RSS FeedPosted by Michael Wonder on 06 Dec 2023
PHARMAC’s new equity policy
6 December 2023 - PHARMAC is drafting its first Equity Policy which outlines the mahi PHARMAC does, can do, or needs ...
Posted by Michael Wonder on 15 Mar 2023
ICER publishes white paper recommending health technology assessment methods that support health equity
15 March 2023 - Informed by expert advisory group and input from external stakeholders, white paper highlights on-going need to ...
Posted by Michael Wonder on 03 Nov 2022
Advocate 'gutted' as PHARMAC reviews blanket funding of child cancer medicines
2 November 2022 - Rule 8.1b of the Pharmaceutical Schedule allows all child cancer medicines to be funded by PHARMAC. ...
Posted by Michael Wonder on 05 Sep 2022
PHARMAC promises equity boost in first official response to independent review
6 September 2022 - PHARMAC will supercharge its commitment to Māori and diverse communities, which could see different medicines funded, ...
Posted by Michael Wonder on 13 Jul 2022
Accelerating pooled licensing of medicines to enhance global production and equitable access
8 July 2022 - From October to November, 2021, the pharmaceutical firms Merck and Pfizer licensed their new COVID-19 oral antiviral ...
Posted by Michael Wonder on 11 Jul 2022
ICER launches initiative to evaluate and advance health technology assessment methods that support health equity
11 July 2022 - Funding from Commonwealth Fund supports a broad based initiative exploring potential changes in all health technology assessment ...
Posted by Michael Wonder on 06 May 2022
Patient reported outcome assessment must be inclusive and equitable
5 May 2022 - Patient reported outcomes are increasingly collected in clinical trials and in routine clinical practice, but strategies ...
Posted by Michael Wonder on 08 Mar 2022
Vaccine approval before Phase 3 trial results: a consequence of vaccine access inequity
2 March 2022 - The final Phase 3 clinical data for CanSino Biologics' adenovirus type 5 vector vaccine show that Ad5-nCoV ...
Posted by Michael Wonder on 02 Feb 2022
Equity in cancer drug access in the UK
1 February 2022 - In draft guidance published on 5 January 2022, NICE announced their decision not to recommend the use ...
Posted by Michael Wonder on 08 Dec 2021
Funding Keytruda for melanoma but not for lung cancer is racist, health advocates say
8 December 2021 - PHARMAC has been accused of institutional racism and breaching the Treaty of Waitangi for funding drugs ...
Posted by Michael Wonder on 11 Nov 2021
Inclusion in health technology assessments: the first step toward equity
10 November 2021 - Many researchers working on health technology assessments are keen to address disparities in health care. ...
Posted by Michael Wonder on 26 Sep 2021
On new recommendation for treatment of COVID-19 patients: WHO calls for equitable access to casirivimab and imdevimab for COVID-19
24 September 2021 - The World Health Organization welcomes the addition of another therapeutic to the world’s arsenal against COVID-19, ...
Posted by Michael Wonder on 19 Aug 2021
Booster shots ‘make a mockery of vaccine equity,’ the WHO’s Africa director says
19 August 2021 - The Africa director at the World Health Organization, Dr. Matshidiso Moeti, criticized the decisions by some ...
Posted by Michael Wonder on 04 Jul 2021
ICER to test principle of fair access to fairly priced pharmaceuticals
2 July 2021 - The controversial approval last month by the FDA of Aduhelm (aducanumab) for patients with early-stage Alzheimer’s disease ...
Posted by Michael Wonder on 07 Feb 2021
Modifying NICE’s approach to equity weighting
7 February 2021 - The UK’s NICE recently launched a consultation on the methods it uses to evaluate new health technologies, ...